A Phase 1A/1B, Two-Stage Study of a PSA/IL-2/GM-CSF Vaccine for the Treatment of PSA Recurrent Prostate Cancer in Hormone-Naive and Hormone-Independent Patients
Latest Information Update: 07 Nov 2021
At a glance
- Drugs PSA-IL2-GM-CSF vaccine (Primary) ; Interleukin-2
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Sponsors Oncobioimune; Theralink Technologies
- 09 Jan 2019 According to an OncBioMune Pharmaceuticals media release, the company now collecting long-term follow-up results for the 1a portion of this trial.
- 07 Sep 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 02 Jul 2018 According to an OncBioMune Pharmaceuticals media release, company is collecting long-term follow-up results for the 1a portion of this trial.